Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
La Pointe JR, Fredette V. Anti-tumor product of bacterial origin. US Patent 3,936,354 dated Feb 3 1976
Lapointe JR, Fredette V. [Nitrosoguanidine-induced attenuated Clostridium perfringens type A mutant in gas gangrene]. Can. J. Microbiol. 21: 1259-1269, 1975. PubMed: 169977
Lapointe JR, Fredette V. [Principle and new media for sporulation of Clostridium perfringens. Preliminary results with an attenuated mutant] Union Med. Can. 104(4): 527-538, 1975. PubMed: 178082
Lapointe JR, Fredette V. [Analysis of the oncolytic properties of Clostridium perfringens. Use of an attenuated mutant and Ehrlich solid carcinoma] Union Med. Can. 104(7): 1070-1077, 1975. PubMed: 169620
